The Net Margin of Cellular Biomedicine Group Inc (CBMG) is
-14704.70%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2019-12-31 |
-14704.70%
|
| 2018-12-31 |
-17355.40%
|
| 2017-12-31 |
-7567.93%
|
| 2016-12-31 |
-4492.28%
|
| 2015-12-31 |
-776.23%
|
| 2014-12-31 |
-2741.88%
|
| 2013-12-31 |
-6900.00%
|
| 2012-12-31 |
-2603.70%
|
| 2011-12-31 |
-1925.00%
|
| 2010-12-31 |
-9.77%
|
| Ticker |
Name |
Value |
|
950220.KQ
|
Neoimmunetech Inc
|
-33533.01%
|
|
EIGR
|
Eiger BioPharmaceuticals Inc
|
-475.26%
|
|
UBX
|
Unity Biotechnology Inc
|
-18842.80%
|
|
VRTX
|
Vertex Pharmaceuticals Incorporated
|
32.94%
|
|
ABBV
|
AbbVie Inc.
|
6.91%
|
|
CRDF
|
Cardiff Oncology, Inc.
|
-7732.04%
|
|
PRQR
|
ProQR Therapeutics NV
|
-258.05%
|
|
REGN
|
Regeneron Pharmaceuticals, Inc.
|
31.41%
|
|
VTGN
|
Vistagen Therapeutics, Inc.
|
-5491.33%
|
|
APS.TO
|
Aptose Biosciences Inc
|
4175.00%
|
|
BLU.TO
|
BELLUS Health Inc
|
-475500.00%
|
|
CUE
|
Cue Biopharma, Inc.
|
-96.85%
|
|
IBIO
|
iBio Inc
|
-33044.00%
|
|
LCTX
|
Lineage Cell Therapeutics Inc
|
-436.47%
|
|
ONCT
|
Oncternal Therapeutics Inc
|
-5029.17%
|
|
AMGN
|
Amgen Inc
|
20.98%
|
|
MRNA
|
Moderna, Inc.
|
-145.16%
|
|
950200.KQ
|
Psomagen Inc
|
-5.04%
|
|
FBRX
|
Forte Biosciences, Inc.
|
-158800.00%
|
|
GILD
|
Gilead Sciences, Inc.
|
28.90%
|
|
OCX
|
OncoCyte Corp
|
-3225.04%
|
|
BYSI
|
Beyondspring Inc
|
-2463.29%
|
|
SPRB
|
Spruce Biosciences, Inc.
|
-1079.94%
|
|
950160.KQ
|
Kolon TissueGene Inc
|
-3733.25%
|
|
ABUS
|
Arbutus Biopharma Corp
|
-237.88%
|
|
IMNM
|
Immunome, Inc.
|
-3059.99%
|
|
KZR
|
Kezar Life Sciences, Inc.
|
-1455.29%
|
|
TRVN
|
Trevena Inc
|
-1289.25%
|
|
AGLE
|
Aeglea Bio Therapeutics Inc
|
-3597.42%
|